Clinical Trial Update: PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) [Phase 2]

View source ↗

Summary

Phase 2 randomized CAPELA trial comparing capecitabine plus elacestrant versus capecitabine alone in estrogen receptor–positive breast cancer; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)
• Xeloda (capecitabine)

Snippet

Sponsor: Kristina A. Fanucci | Conditions: Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: RECRUITING